Search

Your search keyword '"Shivakumar, Yogesh"' showing total 13 results
Start Over Author "Shivakumar, Yogesh"
13 results on '"Shivakumar, Yogesh"'

1. MP41-05 LIQUID-BIOPSY BASED NOVEL mRNA GENOMIC TEST FOR EARLY DETECTION, PROGNOSIS AND MONITORING OF PROSTATE CANCER: A MULTICENTER STUDY

Author

Hashimoto, Yutaka, primary, Verma, Shiv, additional, Deng, Guoren, additional, Chauhan, Dharam P., additional, Nair, Sujit, additional, Chakravarty, Dimple, additional, Yoshino, Hirofumi, additional, Arima, Junya, additional, Tatarano, Shuichi, additional, Liu, Yutong, additional, Hatano, Koji, additional, Shivakumar, Yogesh, additional, Ghosh, Mithua, additional, Krishnappa, Raghunath S., additional, Chandran, Chitra, additional, Ragavan, Narasimhan, additional, Enokida, Hideki, additional, Nonomura, Norio, additional, Balaji, K. C., additional, Rawal, Sudhir K., additional, Tewari, Ashutosh K., additional, Dahiya, Rajvir, additional, and Gupta, Sanjay, additional

Published
2024
Full Text
View/download PDF

2. A novel blood-based mRNA genomic test for screening, early detection, prognosis, and monitoring of prostate cancer: A multicenter study.

Author

Hashimoto, Yutaka, Verma, Shiv, Deng, Guoren, Chauhan, Dharam P, Nair, Sujit, Yoshino, Hirofumi, Arima, Junya, Liu, Yutong, Hatano, Koji, Shivakumar, Yogesh, Krishnappa, Raghunath S., Chandran, Chitra, Ragavan, Narasimhan, Enokida, Hideki, Nonomura, Norio, Balaji, K C, Rawal, Sudhir K, Tewari, Ashutosh K., Dahiya, Rajvir, and Gupta, Sanjay

Published
2024
Full Text
View/download PDF

3. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis

Author

Cappellano, Giuseppe, Woldetsadik, Abiy Demeke, Orilieri, Elisabetta, Shivakumar, Yogesh, Rizzi, Manuela, Carniato, Fabio, Gigliotti, Casimiro Luca, Boggio, Elena, Clemente, Nausicaa, Comi, Cristoforo, Dianzani, Chiara, Boldorini, Renzo, Chiocchetti, Annalisa, Renò, Filippo, and Dianzani, Umberto

Published
2014
Full Text
View/download PDF

4. Kirsten rat sarcoma mutation in South Indians with non-small lung cancer: A cause for concern?

Author

Ghosh, Mithua, primary, Balaram, Gautam, additional, Thomas, Renjan, additional, Ghorpade, SuhasN, additional, Kowsik, PrarthanaV, additional, Dharman, Baby, additional, Shivakumar, Yogesh, additional, Patil, Shekar, additional, Thungappa, SatheeshChiradoni, additional, Shashidhara, HP, additional, Bhattacharjee, Somorat, additional, Susheela, SridharPapaiah, additional, Naik, Radheshyam, additional, Jayappa, SrinivasBelagutty, additional, Nanjaiah, TejaswiniBangalore, additional, Shivalingappa, ShivakumarSwamy, additional, and Ajaikumar, BS, additional

Published
2022
Full Text
View/download PDF

5. Assessment of droplet digital polymerase chain reaction for measuring BCR‐ABL1 in chronic myeloid leukaemia in an international interlaboratory study

Author

Scott, Stuart, primary, Cartwright, Ashley, additional, Francis, Sebastian, additional, Whitby, Liam, additional, Sanzone, A. Pia, additional, Mulder, André, additional, Galimberti, Sara, additional, Dulucq, Stephanie, additional, Mauté, Carole, additional, Lauricella, Calogero, additional, Salmon, Matthew, additional, Rose, Susan, additional, Willoughby, Josh, additional, Boeckx, Nancy, additional, Pallisgaard, Niels, additional, Maier, Jacqueline, additional, Leibundgut, Elisabeth O., additional, Zizkova, Hana, additional, Ling Goh, Liuh, additional, Duong, Chinh, additional, Tang, Wing F., additional, Ma, Edmond, additional, Shivakumar, Yogesh, additional, Beppu, Lan, additional, Bhagavatula, Prasanthi, additional, and Chantry, Andrew, additional

Published
2021
Full Text
View/download PDF

6. Landscape of clinically actionable mutations in breast cancer ‘A cohort study’

Author

Ghosh, Mithua, primary, Naik, Radheshyam, additional, Lingaraju, Sheela Mysore, additional, Susheela, Sridhar Papaiah, additional, Patil, Shekar, additional, Srinivasachar, Gopinath Kodaganur, additional, Thungappa, Satheesh Chiradoni, additional, Murugan, Krithika, additional, Jayappa, Srinivas Belagutty, additional, Bhattacharjee, Somorat, additional, Rao, Nalini, additional, Bandimegal, Mahesh, additional, Krishnappa, Roopesh, additional, Poppareddy, Shashidhara Haragadde, additional, Raghavendrachar, Krishna Chennagiri, additional, Shivakumar, Yogesh, additional, Nagesh, Sunitha, additional, Kodandapani, Ramya, additional, Rajan, Ashwini, additional, Bahadur, Urvashi, additional, Agrawal, Pooja, additional, Ramaswamy, Veena, additional, Nanjaiah, Tejaswini Bangalore, additional, Kunigal, Sateesh, additional, Katragadda, Shanmukh, additional, Manjunath, Ashwini, additional, Ram, Amritanshu, additional, and Ajaikumar, Basavalinga S., additional

Published
2021
Full Text
View/download PDF

7. Kirsten Rat Sarcoma Mutation in South Indians with Non-Small Lung Cancer: A Cause for Concern?

Author

BALARAM, GAUTAM, THOMAS, RENJAN, GHORPADE, SUHAS N., KOWSIK, PRARTHANA V., DHARMAN, BABY, SHIVAKUMAR, YOGESH, PATIL, SHEKAR, THUNGAPPA, SATHEESH CHIRADONI, H. P., SHASHIDHARA, BHATTACHARJEE, SOMORAT, SUSHEELA, SRIDHAR PAPAIAH, NAIK, RADHESHYAM, JAYAPPA, SRINIVAS BELAGUTTY, NANJAIAH, TEJASWINI BANGALORE, SHIVALINGAPPA, SHIVAKUMAR SWAMY, GHOSH, MITHUA, and AJAIKUMAR, B. S.

Published
2022
Full Text
View/download PDF

8. B7h triggering inhibits the migration of tumor cell lines

Author

Dianzani, Chiara, Minelli, Rosalba, Gigliotti, Casimiro Luca, Occhipinti, Sergio, Giovarelli, Mirella, Conti, Laura, Boggio, Elena, Shivakumar, Yogesh, Baldanzi, Gianluca, Malacarne, Valeria, Orilieri, Elisabetta, Cappellano, Giuseppe, Fantozzi, Roberto, Yagi, Junji, Rojo, Josè Maria, Chiocchetti, Annalisa, SBLATTERO, DANIELE, DIANZANI, Umberto, DE CONTI, LAURA, Dianzani, Chiara, Minelli, Rosalba, Gigliotti, Casimiro Luca, Occhipinti, Sergio, Giovarelli, Mirella, Conti, Laura, Boggio, Elena, Shivakumar, Yogesh, Baldanzi, Gianluca, Malacarne, Valeria, Orilieri, Elisabetta, Cappellano, Giuseppe, Fantozzi, Roberto, Sblattero, Daniele, Yagi, Junji, Rojo, Josè Maria, Chiocchetti, Annalisa, Dianzani, Umberto, and DE CONTI, Laura

Subjects
Immunoglobulin Fc Fragment, Lung Neoplasms, Angiogenesis, T cell, Recombinant Fusion Proteins, tumor cells, Human Umbilical Vein Endothelial Cell, Immunology, Hep G2 Cell, Mice, SCID, Biology, SCID, migration, B7h, Matrix-Metalloproteinase inhibitors, Metastasis, Focal adhesion, Inducible T-Cell Co-Stimulator Protein, Inducible T-Cell Co-Stimulator Ligand, Mice, Immune system, Cell Movement, Mice, Inbred NOD, medicine, Human Umbilical Vein Endothelial Cells, Immunology and Allergy, Animals, Humans, Neoplasm Metastasis, Hep G2 Cells, Heterografts, Immunoglobulin Fc Fragments, Neoplasm Transplantation, Animal, medicine.disease, Cell biology, Lung Neoplasm, Neoplasm Metastasi, medicine.anatomical_structure, Cell culture, Cancer cell, Inbred NOD, Hepatocyte growth factor, Heterograft, medicine.drug, Human, Recombinant Fusion Protein
Abstract

Vascular endothelial cells (ECs) and several cancer cells express B7h, which is the ligand of the ICOS T cell costimulatory molecule. We have previously shown that B7h triggering via a soluble form of ICOS (ICOS-Fc) inhibits the adhesion of polymorphonuclear and tumor cell lines to HUVECs; thus, we suggested that ICOS-Fc may act as an anti-inflammatory and antitumor agent. Because cancer cell migration and angiogenesis are crucial for metastasis dissemination, the aim of this work was to evaluate the effect of ICOS-Fc on the migration of cancer cells and ECs. ICOS-Fc specifically inhibited the migration of HUVECs, human dermal lymphatic ECs, and the HT29, HCT116, PC-3, HepG2, JR8, and M14 tumor cell lines expressing high levels of B7h, whereas it was ineffective in the RPMI7932, PCF-2, LM, and BHT-101 cell lines expressing low levels of B7h. Furthermore, ICOS-Fc downmodulated hepatocyte growth factor facilitated the epithelial-to-mesenchymal transition in HepG2 cells. Moreover, ICOS-Fc downmodulated the phosphorylation of focal adhesion kinase and the expression of β-Pix in both HUVECs and tumor cell lines. Finally, treatment with ICOS-Fc inhibited the development of lung metastases upon injection of NOD-SCID-IL2Rγnull mice with CF-PAC1 cells, as well as C57BL/6 mice with B16-F10 cells. Therefore, the B7h−ICOS interaction may modulate the spread of cancer metastases, which suggests the novel use of ICOS-Fc as an immunomodulatory drug. However, in the B16-F10–metastasized lungs, ICOS-Fc also increased IL-17A/RORc and decreased IL-10/Foxp3 expression, which indicates that it also exerts positive effects on the antitumor immune response.

Published
2014

10. ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo

Author

Gigliotti, Casimiro L., primary, Boggio, Elena, additional, Clemente, Nausicaa, additional, Shivakumar, Yogesh, additional, Toth, Erika, additional, Sblattero, Daniele, additional, D’Amelio, Patrizia, additional, Isaia, Giovanni C., additional, Dianzani, Chiara, additional, Yagi, Junji, additional, Rojo, Josè M., additional, Chiocchetti, Annalisa, additional, Boldorini, Renzo, additional, Bosetti, Michela, additional, and Dianzani, Umberto, additional

Published
2016
Full Text
View/download PDF

12. An Indian Study On Comprehensive Analysis Of Brca (Brcam) And Other Germline Mutations (Grm) With A Clinicopathological Association In Breast Cancer.

Author

Kunigal, Sateesh S., ShivaKumar, Yogesh, and Patil, Shekar

Subjects
*BRCA genes, *BREAST cancer, *METASTATIC breast cancer, *FAMILY history (Medicine), *GERM cells
Abstract

Basis of the Study: BRCAm and other GRm testing in early diagnosed and/or metastatic breast cancer (BC) helps in the identification of both unambiguously defined deleterious mutations and sequence variants of unknown clinical significance (VUS). The early detection and identification of these mutations in the proband and the family members help in risk stratification and instituting effective monitoring, surveillance and disease management strategies. This study aimed to systematically review and perform next generation sequencing (NGS) to test for mutations in BRCA1/2 and in additional risk predisposition genes in breast cancer (BC). Methods: 200 unrelated BC patients (early diagnosed and/or advanced/metastatic) aged 26-75 yrs (median age 50.5yrs) diagnosed and referred for genetic testing at HCG from April 2013-17 were consented to be profiled by NGS on MiSeq platform using TruSight Cancer panel (consisting of 94 genes including 13 genes highly associated with risk of inherited breast and/or ovarian cancer) in an IRB-approved, CLIA-compliant prospective study. Data was processed using STRAND software and interpreted using "Strand Omics"platform. The paired tumor sampleswere analysed for pathological stage, histological type and hormonal status. Results: GRm was detected in 50% of the cases screened. Among all mutations detected, BRCA1/2 was found in 54% (31% in BRCA1, 23% in BRCA2) of cases with co mutation of both the genes in 5 cases. Mutation frequencies were higher among high grade IDC with HER2-ve tumors including TNBC (53%, p< 0.001). ). BRCAm are higher in the age group of 25-50 vs. 50-75 yrs. Interestingly, 4 BRCA1 mutations including 3 nonsense and 1 frameshift mutation were found in two unrelated individuals suggesting them to be founder/recurrent mutations in Indian population. The other GRm frequency was also found to be significantly high (46%) and include BRIP1, CHEK2, ERCC2, CDH1, SDHB, APC, MSH6, TP53, PALB2 and RAD51C. Stratification based on age of diagnosis (dx) showed a detection rate of BRCAm and GRm to be significantly higher in the age group of 25-50 yrs (74%) as compared to the 50-75 yrs (26%). Also a strong association of BRCAm and GRm status with the family history (Hx) of BC in 1st or 2nd degree relatives was indicated. Conclusions: In summary, our results in a small cohort showed a high frequency of BRCA1/2 mutations. BRCAm frequency was found to be higher in high grade HER2-/TNBC warranting expanded testing of this subtype to impact disease management with PARP inhibitors and/ or platinum therapy. Identification of non BRCA mutations associated with hereditary BC clearly highlights the utility of germline testing and classifying the variants in larger cohort of BC cases. A strong association of BRCAm and non BRCAm was found with early onset of disease and family history. [ABSTRACT FROM AUTHOR]

Published
2017

13. ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo

Author

Casimiro Luca Gigliotti, Erika Tóth, Daniele Sblattero, Michela Bosetti, Umberto Dianzani, Yogesh Shivakumar, Nausicaa Clemente, Giovanni Carlo Isaia, Junji Yagi, Annalisa Chiocchetti, Chiara Dianzani, Elena Boggio, Renzo Boldorini, Patrizia D'Amelio, José M. Rojo, Gigliotti, Casimiro L., Boggio, Elena, Clemente, Nausicaa, Shivakumar, Yogesh, Toth, Erika, Sblattero, Daniele, D'Amelio, Patrizia, Isaia, Giovanni C., Dianzani, Chiara, Yagi, Junji, Rojo, Josè M., Chiocchetti, Annalisa, Boldorini, Renzo, Bosetti, Michela, and Dianzani, Umberto

Subjects
0301 basic medicine, medicine.medical_specialty, Cellular differentiation, CD14, T cell, Recombinant Fusion Proteins, Immunology, Osteoclasts, Receptors, Fc, Treg regulatory T cell, Biology, Protein Engineering, Bone resorption, Monocytes, Inducible T-Cell Co-Stimulator Protein, 03 medical and health sciences, Inducible T-Cell Co-Stimulator Ligand, Mice, 0302 clinical medicine, Osteoclast, Cell Movement, Internal medicine, medicine, Cathepsin K, Immunology and Allergy, Animals, Humans, Cells, Cultured, Membrane Glycoproteins, Receptor Activator of Nuclear Factor-kappa B, Tartrate-Resistant Acid Phosphatase, RANK Ligand, Cell Differentiation, Cell biology, Resorption, ICOS LIGAND, 030104 developmental biology, medicine.anatomical_structure, Endocrinology, 030215 immunology
Abstract

Osteoblasts, osteocytes, and osteoclasts (OCs) are involved in the bone production and resorption, which are crucial in bone homeostasis. OC hyperactivation plays a role in the exaggerated bone resorption of diseases such as osteoporosis, rheumatoid arthritis, and osteolytic tumor metastases. This work stems from the finding that OCs can express B7h (ICOS-Ligand), which is the ligand of the ICOS T cell costimulatory molecule. Because recent reports have shown that, in endothelial, dendritic, and tumor cells, B7h triggering modulates several activities of these cells, we analyzed the effect of B7h triggering by recombinant ICOS-Fc on OC differentiation and function. The results showed that ICOS-Fc inhibits RANKL-mediated differentiation of human monocyte-derived OC-like cells (MDOCs) by inhibiting the acquirement of the OC morphology, the CD14− cathepsin K+ phenotype, and the expression of tartrate-resistant acid phosphatase, OSCAR, NFATc1, and DC-STAMP. Moreover, ICOS-Fc induces a reversible decrease in the sizes of cells and nuclei and cathepsin K expression in mature MDOCs. Finally, ICOS-Fc inhibits the osteolytic activities of MDOCs in vitro and the development of bone loss in ovariectomized or soluble RANKL-treated mice. These findings open a novel field in the pharmacological use of agonists and antagonists of the ICOS–B7h system.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results